Curaleaf Holdings Inc., a Stamford-based
cannabis company, has bought an institutional investor’s equity stake in Curaleaf International Holdings Ltd., giving it 100% ownership of the European holding company.
The deal was carried out through a put/call option, which gives both the buyer the option to purchase and the seller the option to sell the stake at a specific price.
The undisclosed investor, which acquired the position in 2021, elected to receive subordinate voting shares – which are restricted shares that still provide voting rights – in exchange for the equity in Curaleaf International.
Curaleaf said the acquisition strengthens its control over its European operations, enabling enhanced strategic alignment across international markets.
Curaleaf International consists of a clinic, pharmacy, and laboratory in the UK; cultivation and processing facilities in Portugal; a processing, quality assurance and research site in Spain; a Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and cannabis producer Northern Green Canada.
Curaleaf International’s issuance of the subordinate voting shares was conditionally approved by the Toronto Stock Exchange on June 25, 2025, subject to fulfilling customary listing conditions. The transaction was completed on July 2.
Curaleaf Holdings, which lists its principal business address as 290 Harbor Drive, in Stamford, trades on the Toronto Stock Exchange under the ticker symbol CURLF.
“This consolidation of ownership of our European holding company enables us to streamline decision-making, strengthen alignment across regions, and accelerate our strategic initiatives in Europe with greater autonomy,” Curaleaf Holdings Executive Chairman Boris Jordan said. “This development marks another important milestone in Curaleaf’s continued commitment to international expansion and long-term value creation for shareholders. We thank our partners for their long-standing support and belief in Curaleaf’s future.”
